Comments on “Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial”

2026-07-07

0

PRE

AI

DOI：10.1111/jgh.70558

Original

Original request for help

Share

Save